Premium
Carboxy‐terminal fragment of osteogenic growth peptide regulates myeloid differentiation through RhoA
Author(s) -
Mattii Letizia,
Fazzi Rita,
Moscato Stefania,
Segnani Cristina,
Pacini Simone,
Galimberti Sara,
D'Alessandro Delfo,
Bernardini Nunzia,
Petrini Mario
Publication year - 2004
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.20248
Subject(s) - rhoa , microbiology and biotechnology , pentapeptide repeat , cell growth , chemistry , signal transduction , biology , peptide , biochemistry
The carboxy‐terminal fragment of osteogenic growth peptide, OGP(10–14), is a pentapeptide with bone anabolic effects and hematopoietic activity. The latter activity appears to be largely enhanced by specific growth factors. To study the direct activity of OGP(10–14) on myeloid cells, we tested the pentapeptide proliferating/differentiating effects in HL60 cell line. In this cell line, OGP(10–14) significantly inhibited cell proliferation, and enhanced myeloperoxidase (MPO) activity and nitroblue tetrazolium reducing ability. Moreover, it induced cytoskeleton remodeling and small GTP‐binding protein RhoA activation. RhoA, which is known to be involved in HL60 differentiation, mediated these effects as shown by using its specific inhibitor, C3. Treatment with GM‐CSF had a comparable OGP(10–14) activity on proliferation, MPO expression, and RhoA activation. Further studies on cell proliferation and RhoA activation proved enhanced activity by association of the two factors. These results strongly suggest that OGP(10–14) acts directly on HL60 cells by activating RhoA signaling although other possibilities cannot be ruled out. © 2004 Wiley‐Liss, Inc.